Envisioning a Hepatitis Delta Cure with New Antivirals
2021; Future Medicine; Volume: 16; Issue: 13 Linguagem: Inglês
10.2217/fmb-2021-0177
ISSN1746-0921
AutoresVincent Soriano, Carmen de Mendoza, Pablo Barreiro, Ana Treviño, Octavio Corral,
Tópico(s)Hepatitis C virus research
ResumoFuture MicrobiologyVol. 16, No. 13 EditorialEnvisioning a hepatitis delta cure with new antiviralsVicente Soriano, Carmen de Mendoza, Pablo Barreiro, Ana Treviño & Octavio CorralVicente Soriano *Author for correspondence: E-mail Address: vicente.soriano@unir.nethttps://orcid.org/0000-0002-4624-5199UNIR Health Sciences School & Medical Center, Madrid, Spain, Carmen de MendozaPuerta de Hierro Research Institute & University Hospital, Majadahonda, Madrid, Spain, Pablo BarreiroZendal Hospital, Consejería de Sanidad, Madrid, Spain, Ana TreviñoUNIR Health Sciences School & Medical Center, Madrid, Spain & Octavio CorralUNIR Health Sciences School & Medical Center, Madrid, SpainPublished Online:18 Aug 2021https://doi.org/10.2217/fmb-2021-0177AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antiviralsbulevirtidechronic hepatitis Dcombination therapycureeradicationhepatitis deltaionafarnibtenofovirReferences1. Rizzetto M, Canese MG, Arico S et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 18(12), 997–1003 (1977).Crossref, Medline, CAS, Google Scholar2. Rizzetto M, Hoyer B, Canese MG, Shih J, Purcell R, Gerin J. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc. Natl Acad. Sci. USA 77(10), 6124–6128 (1980).Crossref, Medline, CAS, Google Scholar3. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3(6), 383–403 (2018).Crossref, Medline, Google Scholar4. Chen H, Shen D, Ji D et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut 68(3), 512–521 (2019).Crossref, Medline, CAS, Google Scholar5. Stockdale A, Kreuels B, Henrion M et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. 73(3), 523–532 (2020).Crossref, Medline, Google Scholar6. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut (2021) (in press).Crossref, Google Scholar7. Soriano V, Aguilera A. Hepatitis delta enters a new therapeutic era. J. Infect. Dis. 217(8), 1173–1176 (2018).Crossref, Medline, Google Scholar8. Perez-Vargas J, Amirache F, Boson B et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nat. Commun. 10(1), 2098 (2019).Crossref, Medline, Google Scholar9. Pérez-Vargas J, Pereira de Oliveira R, Jacquet S, Pontier D, Cosset FL, Freitas N. HDV-like viruses. Viruses 13(7), 1207 (2021).Crossref, Medline, Google Scholar10. Fernández-Montero JV, Vispo E, Barreiro P et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin. Infect. Dis. 58(11), 1549–1553 (2014).Crossref, Medline, CAS, Google Scholar11. Farci P, Niro GA, Zamboni F, Diaz G. Hepatitis D virus and hepatocellular carcinoma. Viruses 13(5), 830 (2021).Crossref, Medline, CAS, Google Scholar12. Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J. Hepatol. 73(3), 533–539 (2020).Crossref, Medline, Google Scholar13. Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J. Hepatol. 74(5), 1200–1211 (2021).Crossref, Medline, Google Scholar14. Toy M, Ahishali E, Yurdaydın C. Hepatitis delta virus epidemiology in the industrialized world. AIDS Rev. 22(4), 203–212 (2020).Medline, Google Scholar15. Hung C, Wu S, Lin P et al. Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin. Infect. Dis. 58(11), 1625–1633 (2014).Crossref, Medline, CAS, Google Scholar16. Hamady A, Cooke G, Garvey L. Identification of hepatitis delta superinfection when investigating transaminitis in HIV/HBV coinfection. AIDS 35(10), 1704–1706 (2021).Medline, CAS, Google Scholar17. Soriano V, del Romero J. Rebound in sexually transmitted infections following the success of antiretrovirals for HIV/AIDS. AIDS Rev. 20(4), 187–204 (2018).Medline, Google Scholar18. Deterding K, Wedemeyer H. Beyond pegylated interferon-alpha: new treatments for hepatitis delta. AIDS Rev. 21(3), 126–134 (2019).Crossref, Medline, Google Scholar19. Loureiro D, Castelnau C, Tout I et al. New therapies for hepatitis delta virus infection. Liver Int. 41(Suppl. 1), 30–37 (2021).Crossref, Medline, CAS, Google Scholar20. Masetti C, Aghemo A. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 41(7), 1441–1442 (2021).Crossref, Medline, CAS, Google Scholar21. Asselah T, Loureiro D, Le Gal F et al. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with bulevirtide in real-life. Liver Int. 41(7), 1509–1517 (2021).Crossref, Medline, CAS, Google Scholar22. Wedemeyer H, Schoneweis K, Bogomolov P et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. J. Hepatol. 73(Suppl.), 52–53 (2020).Crossref, Medline, Google Scholar23. Yurdaydin C, Kalban C, Karakaya F et al. Subanalysis of the LOWR HDV-2 study reveals high response rates to lonafarnib in patients with low viral loads. J. Hepatol. 68(Suppl.), 89 (2018).Crossref, Google Scholar24. Rodger A, Cambiano V, Bruun T et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316(2), 171–181 (2016).Crossref, Medline, Google Scholar25. Fernández-Montero JV, Aspinall E, Burns J. Treatment as prevention: should hepatitis C learn the lessons from HIV? AIDS Rev. 19(4), 212–218 (2017).Medline, Google Scholar26. Palom A, Sopena S, Riveiro-Barciela M et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. Aliment. Pharmacol. Ther. 54(4), 462–469 (2021).Crossref, Medline, CAS, Google Scholar27. Hercun J, Kim G, Da B et al. Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy. Aliment. Pharmacol. Ther. 54(2), 176–182 (2021).Crossref, Medline, CAS, Google Scholar28. Soriano V, Vispo E, Sierra-Enguita R et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS 28(16), 2389–2394 (2014).Crossref, Medline, CAS, Google Scholar29. WHO. Combating hepatitis B and C to reach elimination by 2030. WHO Report 2016. Geneva, Switzerland https://apps.who.int/iris/handle/10665/206453Google Scholar30. Boeke C, Adesigbin C, Agwuocha C et al. Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination. BMJ Glob. Health 5(12), e003767 (2020).Crossref, Medline, Google Scholar31. McNaughton A, Lemoine M, van Rensburg C, Matthews P. Extending treatment eligibility for chronic hepatitis B virus infection. Nat. Rev. Gastroenterol. Hepatol. 18(3), 146–147 (2021).Crossref, Medline, Google Scholar32. Soriano V, Gallego L. Viral hepatitis: treating hepatitis C in injection drug users. Nat. Rev. Gastroenterol. Hepatol. 10(10), 568–569 (2013).Crossref, Medline, Google Scholar33. Del Rio C, Springer S. Hepatitis C in the United States: one step forward, two steps back. Am. J. Public Health 111(5), 768–769 (2021).Crossref, Medline, Google Scholar34. Cooke G, Andrieux-Meyer I, Applegate T et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 4(2), 135–184 (2019).Crossref, Medline, Google Scholar35. Cox A, El-Sayed M, Kao J et al. Progress towards elimination goals for viral hepatitis. Nat. Rev. Gastroenterol. Hepatol. 17(9), 533–542 (2020).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 16, No. 13 Follow us on social media for the latest updates Metrics Downloaded 35 times History Received 9 July 2021 Accepted 22 July 2021 Published online 18 August 2021 Published in print September 2021 Information© 2021 Future Medicine LtdKeywordsantiviralsbulevirtidechronic hepatitis Dcombination therapycureeradicationhepatitis deltaionafarnibtenofovirAcknowledgmentsThe authors would like to thank F Gomez-Gallego for helpful comments and discussions.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)